Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma

Journal of Korean Neurosurgical Society

Volumn 54, Issue 6, 2013, Pages 489-495

  Gwak, Ho Shin ^a   Yee, Gi Taek ^a   Park, Chul Kee ^a   Kim, Jin Wook ^a   Hong, Yong Kil ^a   Kang, Seok Gu ^a   Kim, Jeong Hoon ^a   Seol, Ho Jun ^a   Jung, Tae Young ^a   Chang, Jong Hee ^a   Yoo, Heon ^a   Hwang, Jeong Hyun ^a   Kim, Se Hyuk ^a   Park, Bong Jin ^a   Hwang, Sun Chul ^a   Kim, Min Su ^a   Kim, Seon Hwan ^a   Kim, Eun Young ^a   Kim, Ealmaan ^a   Kim, Hae Yu ^a   Ko, Young Cho ^a   Yun, Hwan Jung ^a   Youn, Ji Hye ^a   Kim, Juyoung ^b   Lee, Byeongil ^b   Lee, Seung Hoon ^a   more..

^a Registration Group   (South Korea)

^b Health Insurance Review Agency   (South Korea)

Author keywords

Anaplastic oligoastrocytoma; Anaplastic oligodendroglioma; Chemotherapy; Recurrence; Temozolomide

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CISPLATIN; IRINOTECAN; LOMUSTINE; NIMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHILD; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HISTOLOGY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

EID: 84893516406     PISSN: 20053711     EISSN: 15987876     Source Type: Journal    
DOI: 10.3340/jkns.2013.54.6.489     Document Type: Article

References (34)

1. Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, et al.: Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112: 1139-1146, 2008
2. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al.: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12: 259-266, 2001
3. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al.: Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 24: 4746-4753, 2006
4. Brandes AA, Tosoni A, Vastola F, Pasetto LM, Coria B, Danieli D, et al.: Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer 101: 2079-2085, 2004
5. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al.: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24: 2707-2714, 2006
6. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al.: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12: 2013-2021, 1994
7. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al.: Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. J Clin Oncol 31: 337-343, 2013
8. Chamberlain MC, Glantz MJ: CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. J Neurooncol 89: 231-238, 2008
9. Chamberlain MC, Johnston S: Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 115: 1734-1743, 2009
10. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, et al.: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19: 2449-2455, 2001
11. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, et al.: Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83: 53-60, 2007
12. Ducray F, del Rio MS, Carpentier C, Psimaras D, Idbaih A, Dehais C, et al.: Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. J Neurooncol 101: 457-462, 2010
13. Gan HK, Rosenthal MA, Dowling A, Kalnins R, Algar E, Wong N, et al.: A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Neuro Oncol 12: 500-507, 2009
14. Gaya A, Rees J, Greenstein A, Stebbing J: The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 28: 115-120, 2002
15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
16. Macdonald DR, Gaspar LE, Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27: 573-574, 1990
17. Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, et al.: Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol 92: 57-63, 2009
18. Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, et al.: A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol 89: 187-193, 2008
19. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, et al.: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291, 1992
20. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al.: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522, 2010
21. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG: Salvage chemotherapy for oligodendroglioma. J Neurosurg 85: 597-601, 1996
22. Pobereskin LH, Chadduck JB: Incidence of brain tumours in two English counties: a population based study. J Neurol Neurosurg Psychiatry 69: 464-471, 2000
23. Reifenberger G, Louis DN: Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62: 111-126, 2003
24. Soffietti R, Ruda R, Bradac GB, Schiffer D: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43: 1066-1073, 1998
25. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T: Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79: 153-157, 2006
26. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al.: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31: 344-350, 2013
27. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al.: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715-2722, 2006
28. van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, et al.: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14: 599-602, 2003
29. van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, et al.: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51: 1140-1145, 1998
30. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al.: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21: 2525-2528, 2003
31. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al.: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773, 2009
32. Yang SH, Kim MK, Lee TK, Lee KS, Jeun SS, Park CK, et al.: Temozolomide chemotherapy in patients with recurrent malignant gliomas. J Korean Med Sci 21: 739-744, 2006
33. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al.: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000
34. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762-2771, 1999